Fiche traitement
Fingolimod
Bristol-Myers Squibb • SEP
Suivi actif
À vérifier
Résumé
Fingolimod est développé par Bristol-Myers Squibb. Le traitement est actuellement en À vérifier. Il est associé à SEP. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
À vérifier
Bristol-Myers Squibb
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, …
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
2026-07-13 20:20:29
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
À vérifier
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT06408259, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-07-13 20:20:29
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeÀ vérifier
Études associées7
Publications associées28
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
51 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2011-10-15 | Début de l’étudeNCT01285479 | Registre d’essai clinique |
| 2013-07-26 | Début de l’étudeNCT01892722 | Registre d’essai clinique |
| 2020-11-02 | Début de l’étudeNCT04517552 | Registre d’essai clinique |
| 2021-09-09 | Début de l’étudeNCT05528666 | Registre d’essai clinique |
| 2021-09-17 | Fin de l’étude prévue / enregistréeNCT05528666 | Registre d’essai clinique |
| 2022-01-19 | Début de l’étudeNCT05423769 | Registre d’essai clinique |
| 2022-05-19 | Début de l’étudeNCT05123703 | Registre d’essai clinique |
| 2023-11-30 | Fin de l’étude prévue / enregistréeNCT05423769 | Registre d’essai clinique |
| 2024-05-29 | Fin de l’étude prévue / enregistréeNCT01285479 | Registre d’essai clinique |
| 2025-04-08 | Début de l’étudeNCT06408259 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT01285479 | Registre d’essai clinique |
| 2026-07-08 | PublicationEffects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro. | Current neuropharmacology |
| 2026-07-08 | PublicationImpact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion. | Multiple sclerosis (Houndmills, Basingstoke, England) |
| 2026-07-10 | PublicationThe impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry. | Journal of neurology |
| 2026-07-10 | PublicationThe Role of Sphingosine-1-Phosphate Signaling in Cerebral Ischemia/Reperfusion Injury and Alzheimer's Disease Pathology. | International journal of molecular sciences |
| 2026-07-10 | PublicationFingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner. | Cellular and molecular neurobiology |
| 2026-07-13 | Dernière mise à jour du registreNCT01285479 | Registre d’essai clinique |
| 2026-07-13 | Dernière mise à jour des donnéesFingolimod | Biomedical Watch |
| 2026-07-14 | PublicationResponse to "Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims". | Spinal cord |
| 2026-07-14 | PublicationNanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims. | Spinal cord |
| 2026-07-18 | Création de l’enregistrementNCT05528666 | Registre d’essai clinique |
| 2026-07-18 | PublicationIGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis. | Cell communication and signaling : CCS |
| 2026-07-22 | Création de l’enregistrementNCT05423769 | Registre d’essai clinique |
| 2026-07-29 | PublicationMicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review. | International journal of molecular sciences |
| 2026-08-08 | PublicationDifferential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort. | Multiple sclerosis and related disorders |
| 2026-08-08 | PublicationReal-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study. | Multiple sclerosis and related disorders |
| 2026-08-08 | PublicationSerum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. | JAMA neurology |
| 2026-08-13 | Création de l’enregistrementNCT01892722 | Registre d’essai clinique |
| 2026-08-13 | PublicationImmunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study. | Frontiers in immunology |
| 2026-08-13 | PublicationTreatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study. | Multiple sclerosis (Houndmills, Basingstoke, England) |
| 2026-08-13 | PublicationSafety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. | BMC neurology |
| 2026-08-13 | PublicationAnti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD. | CNS drugs |
| 2026-08-13 | PublicationEfficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study. | Journal of neurology |
| 2026-08-13 | PublicationA tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy. | Materials today. Bio |
| 2026-08-13 | PublicationNatalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. | Health technology assessment (Winchester, England) |
| 2026-08-16 | PublicationThe contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. | Pflugers Archiv : European journal of physiology |
| 2026-08-16 | PublicationMitochondrial bioenergetic remodeling underlies fingolimod-induced immunometabolic adaptation in multiple sclerosis. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |
| 2026-08-16 | PublicationElectronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study. | JMIR mHealth and uHealth |
| 2026-08-16 | PublicationReal-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. | Therapeutic advances in neurological disorders |
| 2026-08-16 | PublicationComparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. | Journal of neurology, neurosurgery, and psychiatry |
| 2026-08-16 | PublicationEffect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review. | The Annals of pharmacotherapy |
| 2026-08-16 | PublicationReal-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis. | Neurology and therapy |
| 2026-08-16 | PublicationFingolimod induces cytotoxic stress and apoptosis-like cell death in drug-sensitive and P-glycoprotein-overexpressing acute myeloid leukemia cells. | Biochemical and biophysical research communications |
| 2026-08-16 | PublicationInvestigating FTY720-NF immunomodulation of key lipid, gene, and protein mediators to enhance oral tissue regeneration. | Biomaterials advances |
| 2026-08-26 | Création de l’enregistrementNCT04517552 | Registre d’essai clinique |
| 2026-09-01 | Création de l’enregistrementNCT05123703 | Registre d’essai clinique |
| 2026-09-11 | Création de l’enregistrementNCT06408259 | Registre d’essai clinique |
| 2027-07-08 | Fin de l’étude prévue / enregistréeNCT04517552 | Registre d’essai clinique |
| 2029-09-17 | Fin de l’étude prévue / enregistréeNCT05123703 | Registre d’essai clinique |
| 2030-02-18 | Fin de l’étude prévue / enregistréeNCT01892722 | Registre d’essai clinique |
| 2036-07-13 | Fin de l’étude prévue / enregistréeNCT06408259 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
7 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | Phase 3 | RECRUITING | United States, Australia, Italy, Mexico, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey (Türkiye) | Bristol-Myers Squibb |
| NCT05123703 | Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | ACTIVE_NOT_RECRUITING | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Estonia, France, Germany, Greece, Hungary, India, Italy, Latvia, Mexico, Morocco, Poland, Portugal, Romania, … | Hoffmann-La Roche |
| NCT04517552 | Investigation of Inflammation Using [C-11]-CS1P1 | À vérifier | ACTIVE_NOT_RECRUITING | United States | Tammie L. S. Benzinger, MD, PhD |
| NCT01892722 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | Phase 3 | ACTIVE_NOT_RECRUITING | United States, Australia, Austria, Brazil, Bulgaria, Canada, Croatia, Estonia, France, Germany, Italy, Latvia, Lithuania, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Serbia, … | Novartis Pharmaceuticals |
| NCT05423769 | Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt | À vérifier | COMPLETED | Egypt | Hikma Pharmaceuticals LLC |
| NCT05528666 | Risk Perception in Multiple Sclerosis | À vérifier | COMPLETED | United States | Novartis Pharmaceuticals |
| NCT01285479 | The Gilenya Pregnancy Registry | À vérifier | COMPLETED | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, … | Novartis Pharmaceuticals |
Publications liées
28 publication(s)Publications liées
28 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. Voir source | 39384640 | 10.1007/s00424-024-03029-5 | Pflugers Archiv : European journal of physiology | |
| Mitochondrial bioenergetic remodeling underlies fingolimod-induced immunometabolic adaptation in multiple sclerosis. Voir source | 42570637 | 10.1016/j.biopha.2026.119836 | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | |
| Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study. Voir source | 36197713 | 10.2196/38709 | JMIR mHealth and uHealth | |
| Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. Voir source | 42602134 | 10.1177/17562864261472650 | Therapeutic advances in neurological disorders | |
| Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. Voir source | 42161588 | 10.1136/jnnp-2026-338424 | Journal of neurology, neurosurgery, and psychiatry | |
| Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review. Voir source | 41482809 | 10.1177/10600280251407146 | The Annals of pharmacotherapy | |
| Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis. Voir source | 42321508 | 10.1007/s40120-026-00968-2 | Neurology and therapy | |
| Fingolimod induces cytotoxic stress and apoptosis-like cell death in drug-sensitive and P-glycoprotein-overexpressing acute myeloid leukemia cells. Voir source | 42269275 | 10.1016/j.bbrc.2026.154118 | Biochemical and biophysical research communications | |
| Investigating FTY720-NF immunomodulation of key lipid, gene, and protein mediators to enhance oral tissue regeneration. Voir source | 42161013 | 10.1016/j.bioadv.2026.214952 | Biomaterials advances | |
| Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study. Voir source | 30090102 | 10.3389/fimmu.2018.01693 | Frontiers in immunology | |
| Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study. Voir source | 42218618 | 10.1177/13524585261448789 | Multiple sclerosis (Houndmills, Basingstoke, England) | |
| Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. Voir source | 41420217 | 10.1186/s12883-025-04514-9 | BMC neurology | |
| Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD. Voir source | 42334795 | 10.1007/s40263-026-01311-x | CNS drugs | |
| Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study. Voir source | 42371147 | 10.1007/s00415-026-13960-5 | Journal of neurology | |
| A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy. Voir source | 42576991 | 10.1016/j.mtbio.2026.103514 | Materials today. Bio | |
| Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. Voir source | 42579606 | 10.3310/GJHT1811 | Health technology assessment (Winchester, England) | |
| Differential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort. Voir source | 42107470 | 10.1016/j.msard.2026.107220 | Multiple sclerosis and related disorders | |
| Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study. Voir source | 41518821 | 10.1016/j.msard.2025.106947 | Multiple sclerosis and related disorders | |
| Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. Voir source | 42545715 | 10.1001/jamaneurol.2026.2500 | JAMA neurology | |
| MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review. Voir source | 42511484 | 10.3390/ijms27146138 | International journal of molecular sciences | |
| IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis. Voir source | 42458462 | 10.1186/s12964-026-03057-x | Cell communication and signaling : CCS | |
| Response to "Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims". Voir source | 42443564 | 10.1038/s41393-026-01240-y | Spinal cord | |
| Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims. Voir source | 42443565 | 10.1038/s41393-026-01241-x | Spinal cord | |
| The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry. Voir source | 42283727 | 10.1007/s00415-026-13885-z | Journal of neurology | |
| The Role of Sphingosine-1-Phosphate Signaling in Cerebral Ischemia/Reperfusion Injury and Alzheimer's Disease Pathology. Voir source | 42352925 | 10.3390/ijms27125200 | International journal of molecular sciences | |
| Fingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner. Voir source | 42420746 | 10.1007/s10571-026-01774-y | Cellular and molecular neurobiology | |
| Effects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro. Voir source | 42381150 | 10.2174/011570159X430149260302072845 | Current neuropharmacology | |
| Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion. Voir source | 42384032 | 10.1177/13524585261459228 | Multiple sclerosis (Houndmills, Basingstoke, England) |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-07-13 20:20:29
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.